Home › Trials › NCT05203172

Continued access to encorafenib and binimetinib for previous trial participants

ENCORAFENIB/BINIMETINIB MASTER PROTOCOL: AN OPEN-LABEL CONTINUATION STUDY FOR PARTICIPANTS CONTINUING FROM ENCORAFENIB/BINIMETINIB CLINICAL STUDIES

PHASE4 · Pfizer · NCT05203172

This study is for people who have previously taken the medications encorafenib and binimetinib and want to continue using them safely for up to five years if they are still benefiting from the treatment.

Quick facts

PhasePHASE4
Study typeInterventional
Enrollment46 (estimated)
Ages18 Years and up
SexAll
SponsorPfizer (industry)
Drugs / interventionsbinimetinib
Locations67 sites (Phoenix, Arizona and 66 other locations)
Trial IDNCT05203172 on ClinicalTrials.gov

What this trial studies

The FLOTILLA study aims to provide ongoing access to the medications encorafenib and binimetinib for participants who have previously benefited from these treatments in earlier clinical trials. This open-label continuation study allows eligible participants to receive the same dosage and frequency of the medications for up to five years, ensuring safety follow-up and monitoring. Participants must have been part of prior studies involving these drugs and must still be experiencing clinical benefits as determined by their study doctor.

Who should consider this trial

Good fit: Ideal candidates are individuals who have participated in prior clinical trials of encorafenib and/or binimetinib and are still deriving clinical benefit from these treatments.

Not a fit: Patients who have not previously enrolled in a study involving encorafenib or binimetinib will not benefit from this study.

Why it matters

Potential benefit: If successful, this study could provide continued treatment options for patients with solid tumors who have previously responded well to encorafenib and binimetinib.

How similar studies have performed: Other studies involving encorafenib and binimetinib have shown promise, indicating that this continuation approach may build on previously established benefits.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Any participant who is receiving study intervention and deriving clinical benefit (as determined by the principal investigator) in an encorafenib/binimetinib Parent Study, with no ongoing NCI CTCAE version 4.03 Grade ≥3 or intolerable Grade 2 AEs considered to be related to study treatment.
* Participants must agree to follow the reproductive criteria as outlined in the applicable Encorafenib/Binimetinib Continuation Sub-Study Protocol.

Exclusion Criteria:

* Any medical reason that, in the opinion of the investigator or sponsor, precludes the participant from inclusion in the study.

Where this trial is running

Phoenix, Arizona and 66 other locations

+17 more sites — see ClinicalTrials.gov for the full list.

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.

View on ClinicalTrials.gov →

Conditions: Solid Tumors

Last reviewed 2026-05-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.